EC Pulmonology And Respiratory Medicine
Review Article Volume 15 Issue 11 - 2026

The Factual Aspects of Acute Nonspecific Inflammation of Lung Tissue and their Role in Addressing this Problem

Igor Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, MD, Professor, Retired, Renton, WA, USA.
Received: September 24, 2026; Published: October 15, 2026



Acute nonspecific inflammation of lung tissue—or acute pneumonia (AP)—has remained a major, pressing issue in recent decades, characterized by a lack of treatments with proven efficacy and rising mortality rates. An analysis of the evolution of therapeutic approaches reveals the decisive impact that the advent of antibiotics had on prevailing concepts of the disease; this factor shaped the subsequent development of the professional understanding of AP’s nature. Today, alongside the negative consequences of the “antibiotic era,” the primary obstacle to resolving this issue lies in the expert community’s views regarding its fundamental nature.

Keywords: Acute Inflammation; Nonspecific Etiology; Antibiotics; Pathogenesis; Changes in the Etiology of the Disease; The Exclusion of Antibiotics; Distortions in Professional Training

  1. Obianyo CM., et al. “Trends and disparities in pneumonia-related mortality in the U.S. population: A nationwide analysis using the CDC WONDER data”. Cureus 5 (2025): e83371.
  2. Karim R., et al. “Clinical findings and radiological evaluation of WHO-defined severe pneumonia among hospitalized children”. Cureus1 (2023): e33804.
  3. Dion CF and Ashurst JV. “Streptococcus pneumoniae”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2026).
  4. Pneumonia. Prevention and Control. Pneumonia. CDC (2023).
  5. Podolsky SH. “The changing fate of pneumonia as a public health concern in 20th-century America and beyond”. American Journal of Public Health 12 (2005): 2144-2154.
  6. A Putot., et al. “Comprehensive management of pneumonia in older patients”. European Journal of Internal Medicine 135 (2025): 14-24.
  7. R Cavallazzi and JA Ramirez. “Definition, epidemiology, and pathogenesis of severe community-acquired pneumonia”. Seminars in Respiratory and Critical Care Medicine2 (2024): 143-157.
  8. Pickens CI., et al. “Microbiology of severe community-acquired pneumonia and the role of rapid molecular techniques”. Seminars in Respiratory and Critical Care Medicine2 (2024): 158-168.
  9. Nuzzo JB and Ledesma JR. “Why did the best prepared country in the world fare so poorly during COVID?” Journal of Economic Perspectives 37 (2023): 3-22.
  10. Mathieu E., et al. “Coronavirus Pandemic (COVID-19)". Our World in Data (2025).
  11. Avery OT., et al. “Acute lobar pneumonia: prevention and serum treatment”. Monographs of the Rockefeller Institute for Medical Research. Rockefeller Institute for Medical Research, New York (1917).
  12. Cole RI. “Acute pulmonary infections”. De La Mar Lectures. Williams & Wilkins, Baltimore (1927-1928).
  13. Sutliff WD and Finland M. “The significance of the newly classified types of pneumococci in disease: types IV to XX inclusive”. Journal of the American Medical Association 17 (1933): 1289-1295.
  14. Heffron R. “Pneumonia, with special reference to pneumococcus lobar pneumonia”. Cambridge: Harvard University Press (1939).
  15. Small JT. “A short history of the pneumococcus with special reference to lobar pneumonia”. Edinburgh Medical Journal 3 (1948): 129-141.
  16. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 3 (1942): 386-389.
  17. Kirby WM. “Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci”. Science 2579 (1944): 452-453.
  18. “MRSA History Timeline: The First Half-Century, 1959-2009". The University of Chicago Medical Center (2010).
  19. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
  20. Kyriazopoulou E., et al. “BioFire® FilmArray® pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial”. Infectious Diseases and Therapy 3 (2021): 1437-1449.
  21. Enne VI., et al. “Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study”. Thorax 12 (2022): 1220-1228.
  22. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Diseases 7 (2019): 1166-1171.
  23. B Ponnuthurai., et al. “Etiological and clinical profile of virus-associated community-acquired pneumonia in adults”. Chest Infections6 (2020): A55.
  24. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
  25. Musher DM., et al. “Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus”. Clinical Infectious Diseases 10 (2017): 1736-1744.
  26. Olarte L., et al. “Higher-valent pneumococcal conjugate vaccines—perspective for 2026”. JAMA Internal Medicine 12 (2025): 1493-1494.
  27. Lansbury L., et al. “Pneumococcal pneumonia trends in adults hospitalised with community-acquired pneumonia over 10 years (2013-2023) and the role of serotype 3”. Thorax 2 (2025): 86-96.
  28. WHO Revised global burden of disease 2002 estimates (2004).
  29. Ruuskanen O., et al. “Viral pneumonia". Lancet 9773 (2011): 1264-1275.
  30. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): 808-810.
  31. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy11 (2020): 3386-3390.
  32. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases 9 (2020): 2459-2468.
  33. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 8 (2020): 614-616.
  34. National Center for Emerging and Zoonotic Infectious Diseases (March 21, 2024). Climate and Infectious Diseases.
  35. LO Gostin and GK Gronvall. “The origins of covid-19 - why it matters (and why it doesn’t)”. New England Journal of Medicine35 (2023): 2305-2308.
  36. Anderer S. “CDC reports increase in Candida auris infections”. Journal of the American Medical Association 9 (2026): 728.
  37. Ding H., et al. “Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital”. Microbiology Spectrum 8 (2024): e00792-24.
  38. Sakamoto Y., et al. “In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study”. BMC Pulmonary Medicine 1 (2021): 345.
  39. CDC, Saving Lives. Protecting People. Methicillin-resistant Staphylococcus aureus (MRSA). Healthcare Settings (2023).
  40. Albrich WC and Harbarth S. “Health-care workers: Source, vector, or victim of MRSA?” Lancet Infectious Diseases 5 (2008): 289-301.
  41. Aubry-Damon H., et al. “Antimicrobial resistance in commensal flora of pig farmers”. Emerging Infectious Diseases 5 (2004): 873-879.
  42. Graveland H., et al. “Methicillin resistant Staphylococcus aureus ST398 in veal calf farming: human MRSA carriage related with animal antimicrobial usage and farm hygiene”. PLoS ONE6 (2010): e10990.
  43. Giri S., et al. “Prevalence of methicillin-resistant Staphylococcus aureus carriage among healthcare workers in South Asia in non-outbreak settings: A systematic review and meta-analysis”. American Journal of Infection Control 2 (2022): 184-193.
  44. Azzam A., et al. “Prevalence, antibiogram, and risk factors of methicillin-resistant Staphylococcus aureus (MRSA) asymptomatic carriage in Africa: a systematic review and meta-analysis”. BMC Infectious Diseases 1 (2025): 505.
  45. Blood pressure.
  46. Olivia Vynn. Cardiology secrets. Chapter 41. Adair Edition: 2, illustrated Published by Elsevier Health Sciences, ISBN 1-56053-420-6, 978-1-56053-420 (2001): 210.
  47. I Klepikov. Myths, legends and real facts about acute lung inflammation. Cambridge Scholars Publishing. ISBN: 1-0364-0293-2, ISBN13: 978-1-0364-0293-8 (2024): 338.
  48. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archiv – European Journal of Physiology 236 (1935): 206-219.
  49. Singer M., et al. “The third international consensus definitions for sepsis and septic shock (Sepsis-3)”. Journal of the American Medical Association8 (2016): 801-810.
  50. Jungian Chen., et al. “Performance of CURB-65, PSI, and APACHE-II for predicting COVID-19 pneumonia severity and mortality”. European Journal of Inflammation 19 (2021).
  51. Guarino M., et al. “2023 update on sepsis and septic shock in adult patients: Management in the emergency department”. Journal of Clinical Medicine 9 (2023): 3188.
  52. Torres LK., et al. “Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimation”. Thorax 12 (2021): 1176-1185.
  53. The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network., et al. “Early restrictive or liberal fluid management for sepsis-induced hypotension”. New England Journal of Medicine 6 (2023): 499-510.
  54. World Health Organization. Antimicrobial resistance (2023).
  55. Madhavi Thara. “Antibiotic Stewardship”. Medicon Medical Sciences3 (2024): 01-02.

Igor Klepikov. “The Factual Aspects of Acute Nonspecific Inflammation of Lung Tissue and their Role in Addressing this Prob- lem”. EC Pulmonology and Respiratory Medicine 15.11 (2026): 01-10.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net